Literature DB >> 1916039

Effect of omeprazole on nocturnal intragastric pH in cirrhotics with inadequate antisecretory response to ranitidine.

S Walker1, U Klotz, A Sarem-Aslani, G Treiber, J C Bode.   

Abstract

Failure of acid suppression by H2-receptor antagonists has been observed, and recently we have found a higher frequency of patients with inadequate antisecretory response among patients with cirrhosis of the liver. In the present study comprising 16 cirrhotics with inadequate antisecretory response to 300 mg of ranitidine, we tested the effect of 40 mg omeprazole. Nighttime intragastric pH was continuously monitored, and a rise in the intragastric pH above 4.0 for more than 6 h following the oral dose at 18.00 h was considered as response. The median pH profile during the omeprazole treatment was significantly higher than with ranitidine (p less than or equal to 0.001). In contrast to 300 mg ranitidine, which despite sufficient plasma levels 2 and 4 h after intake (762 +/- 431 and 802 +/- 668 ng/ml) resulted in a rise in the nighttime intragastric pH above 4 only for 1.8 +/- 1.7 h, after omeprazole for at least 5 days, the intragastric pH was for 10.1 +/- 2.4 of 12 h above 4 during the night (p less than 0.001). The omeprazole plasma levels were 611 +/- 323 and 881 +/- 533 ng/ml after 2 and 4 h. The data obtained with intragastric pH monitoring indicate that the H+K(+)-ATPase inhibitor omeprazole is able to overcome the H2-blocker resistance in cirrhotics.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916039     DOI: 10.1159/000200691

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

1.  H2-receptor antagonist nonresponders and omeprazole.

Authors:  S Walker; G Treiber; A Sarem-Aslani; U Klotz
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

2.  The effect of intravenous ranitidine on the intragastric pH of preterm infants receiving dexamethasone.

Authors:  E J Kelly; S L Chatfield; K G Brownlee; P C Ng; S J Newell; P R Dear; J N Primrose
Journal:  Arch Dis Child       Date:  1993-07       Impact factor: 3.791

3.  PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis.

Authors:  Mauricio Garcia-Saenz-de-Sicilia; Francisco Sanchez-Avila; Norberto-C Chavez-Tapia; Gustavo Lopez-Arce; Sandra Garcia-Osogobio; Roberto Ruiz-Cordero; Felix-I Tellez-Avila
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

Review 4.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

5.  Safe use of proton pump inhibitors in patients with cirrhosis.

Authors:  Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; S Froukje Harkes-Idzinga; Nicole G M Hunfeld; Herold J Metselaar; Margje H Monster-Simons; Sandra A W van Putten; Katja Taxis; Sander D Borgsteede
Journal:  Br J Clin Pharmacol       Date:  2018-06-07       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.